MiMedx Net Receivables vs Accounts Payable Analysis
| MDXG Stock | USD 9.46 0.29 2.97% |
MiMedx financial indicator trend analysis is infinitely more than just investigating MiMedx Group recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MiMedx Group is a good investment. Please check the relationship between MiMedx Net Receivables and its Accounts Payable accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
Net Receivables vs Accounts Payable
Net Receivables vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MiMedx Group Net Receivables account and Accounts Payable. At this time, the significance of the direction appears to have almost no relationship.
The correlation between MiMedx's Net Receivables and Accounts Payable is 0.17. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of MiMedx Group, assuming nothing else is changed. The correlation between historical values of MiMedx's Net Receivables and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of MiMedx Group are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Receivables i.e., MiMedx's Net Receivables and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.17 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Net Receivables
Accounts Payable
An accounting item on the balance sheet that represents MiMedx obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of MiMedx Group are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from MiMedx's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MiMedx Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. At this time, MiMedx's Enterprise Value Multiple is most likely to increase significantly in the upcoming years. The MiMedx's current Enterprise Value is estimated to increase to about 1 B, while Selling General Administrative is projected to decrease to roughly 123.2 M.
| 2021 | 2023 | 2024 (projected) | Non Recurring | 53K | 47.7K | 45.3K | Reconciled Depreciation | 5.2M | 3.6M | 4.6M |
MiMedx fundamental ratios Correlations
Click cells to compare fundamentals
MiMedx Account Relationship Matchups
High Positive Relationship
High Negative Relationship
MiMedx fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 56.7M | 50.4M | 35.0M | 35.1M | 37.0M | 22.9M | |
| Common Stock Shares Outstanding | 105.6M | 108.3M | 110.4M | 112.9M | 146.0M | 94.7M | |
| Other Liab | 621K | 3.8M | 4.9M | 2.3M | 2.1M | 2.6M | |
| Net Tangible Assets | 6.6M | 91.4M | (25.3M) | (43.8M) | (39.4M) | (37.5M) | |
| Other Assets | 443K | 375K | 186K | 148K | 133.2K | 126.5K | |
| Property Plant Equipment | 15.7M | 11.4M | 13.9M | 11.3M | 12.9M | 10.9M |
Currently Active Assets on Macroaxis
When determining whether MiMedx Group is a strong investment it is important to analyze MiMedx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MiMedx's future performance. For an informed investment choice regarding MiMedx Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.1) | Earnings Share 0.57 | Revenue Per Share 2.447 | Quarterly Revenue Growth 0.029 | Return On Assets 0.1838 |
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.